Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）

Not yet recruitingOBSERVATIONAL

Enrollment

3,000

Participants

Timeline

Start Date

August 10, 2025

Primary Completion Date

August 10, 2027

Study Completion Date

August 10, 2030

Conditions

Vulvovaginal Candidiasis

Interventions

DRUG

Oteseconazole (VT-1161) 150mg capsule

Subjects with SVVC will be treated by Oteseconazole with 600 mg (150 mg per capsule) on D1, 450 mg on D2

All Listed Sponsors

lead

Beijing Tsinghua Chang Gung Hospital

OTHER

NCT07044947 - Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC） | Biotech Hunter | Biotech Hunter